The cherry on top of our season on HDFN and alloimmunization. This week we're talking about the future potential medical therapies for this disease including nipocalimab. See below for the episode outline and topics Dr. Moise discusses this week!
- The neonatal Fc receptor is the FcRN (Neonatal crystallizable fragrant receptor)
- Where FcRN receptors are located in the human body
- Endothelial cells of blood vessels in the skin & muscle
- Placenta
- Function of FcRN receptors
- Definition an FcRN blocker
- Monoclonal antibody or fragment that blocks the FcRN by connecting to it
- How monoclonal antibodies are made
- Human applications for FcRN blockers
- Vvygart made by Argenx for myasthenia gravis
- Warm autoimmune hemolytic anemia
- Idiopathic thrombocytopenia purpura (ITP)
- Chronic demyelinating polyneuropathy
- Pemphigus vulgaris
- Grave’s exophthalmos
- Autoimmune disease, the inflammatory pathway and the FcRN blockers role in the bigger picture
- How FcRN blocker medications are administered
- How an FcRN blocker could be used in pregnancy
- Diseases in pregnancy that could potentially be treated with an FcRN blocker:
- Hemolytic Disease of the Fetus & Newborn (HDFN)
- Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT)
- Gestational Alloimmune Liver Disease (GALD)
- Congenital Heart Block / Neonatal Lupus
- Current drug trials for FcRN blockers in pregnancy
- FDA drug trial process – pre-clinical, phase I, phase II, phase III, and phase IV for drug trials
- Potential risks of FcRN blockers
- How FcRN blockers may affect vaccines in pregnancy
- Other clinical conditions where FcRN blockers have been successfully used
Send us your questions on HDFN & alloimmunization for a Q&A episode! Email us at newswombpodcast@gmail.com
